Zacks Investment Research on MSN
Masimo SET shows accurate pulse oximetry in newborns of all skin tones
Masimo MASI recently reported findings from the NeoPODS study, a large prospective real-world evaluation of its SET pulse oximetry technology in critically ill newborns. The study demonstrated less ...
Masimo secured FDA clearance for its Stork baby monitoring system that can help track certain vital signs in healthy infants up to 18 months old and provide alarms to parents or caregivers. The newly ...
Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET ® pulse oximetry among ...
Masimo, the health technology company that made headlines last winter over a dispute with Apple and its blood oxygen sensing technology, said Monday that its wearable Stork baby monitor is now cleared ...
Masimo’s NeoPODS study in critically ill newborns found its SET pulse oximetry technology delivered consistent accuracy across all skin tones, with less than 1% bias. The findings address longstanding ...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in innovative monitoring technologies used in top hospitals, announced today FDA clearance of Stork™, a revolutionary baby ...
CHICAGO & IRVINE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) and Masimo (Nasdaq: MASI) today announced a joint agreement to integrate Masimo Signal Extraction Technology® (SET®) pulse ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results